Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 1, 2011, Pages 70-76

  van Breemen, Mariëlle J ^a   Rombach, Saskia M ^a   Dekker, Nick ^a   Poorthuis, Ben J ^a   Linthorst, Gabor E ^a   Zwinderman, Aeilko H ^a   Breunig, Frank ^b   Wanner, Christoph ^b   Aerts, Johannes M ^a   Hollak, Carla E ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Enzyme replacement therapy (ERT); Fabry disease; Globotriaosylsphingosine

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; ALPHA GALACTOSIDASE; GLOBOTRIASYLSPHINGOSINE; NEUTRALIZING ANTIBODY; SPHINGOSINE DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; ENZYME REPLACEMENT; FABRY DISEASE; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ALPHA-GALACTOSIDASE; ANTIBODIES; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; ENZYME REPLACEMENT THERAPY; FABRY DISEASE; FEMALE; GLYCOLIPIDS; HUMANS; ISOENZYMES; LIPIDS; MALE; MIDDLE AGED; SPHINGOLIPIDS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78650275925     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2010.09.007     Document Type: Article

References (46)

1. Brady R.O., Gal A.E., Bradley R.M., Martensson E., Warshaw A.L., Laster L. Enzymatic defect in Fabry's disease. Ceramidetrihexosidase deficiency. N Engl J. Med. 1967, 276:1163-1167.
2. Desnick R.J., Ioannou Y.A., Eng C.M. α-Galactosidase A deficiency: Fabry disease. The metabolic and molecular bases of inherited disease 2001, 3733-3774. McGraw-Hill, New York. 8th ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
3. MacDermot K.D., Holmes A., Miners A.H. Natural history of Fabry disease in affected males and obligate carrier females. J. Inherit. Metab. Dis. 2001, 24(Suppl 2):13-14.
4. Vedder A.C., Linthorst G.E., van Breemen M.J., Groener J.E., Bemelman F.J., Strijland A., Mannens M.M., Aerts J.M., Hollak C.E. The Dutch Fabry cohort: diversity of clinical manifestations and Gb3 levels. J. Inherit. Metab. Dis. 2007, 30:68-78.
5. Elleder M., Bradova V., Smid F., Budesinsky M., Harzer K., Kustermann-Kuhn B., Ledvinova J., Belohlavek M., Kral V., Dorazilova V. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch. A Pathol. Anat. Histopathol. 1990, 417:449-455.
6. Nakao S., Kodama C., Takenaka T., Tanaka A., Yasumoto Y., Yoshida A., Kanzaki T., Enriquez A.L., Eng C.M., Tanaka H., Tei C., Desnick R.J. Fabry disease: detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype. Kidney Int. 2003, 64:801-807.
7. Mehta A., Ricci R., Widmer U., Dehout F., Garcia de Lorenzo A., Kampmann C., Linhart A., Sunder-Plassmann G., Ries M., Beck M. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey. Eur. J. Clin. Invest. 2004, 34:236-242.
8. Eng C.M., Fletcher J., Wilcox W.R., Waldek S., Scott C.R., Sillence D.O., Breunig F., Charrow J., Germain D.P., Nicholls K., Banikazemi M. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J. Inherit. Metab. Dis. 2007, 30:184-192.
9. Schiffmann R. Fabry disease. Pharmacol. Ther. 2009, 122:65-77.
10. Saito S., Ohno K., Sese J., Sugawara K., Sakuraba H. Prediction of the clinical phenotype of Fabry disease based on protein sequential and structural information. J. Hum. Genet. 2010, 55:175-178.
11. Wu J.C., Ho C.Y., Skali H., Abichandani R., Wilcox W.R., Banikazemi M., Packman S., Sims K., Solomon S.D. Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity. Eur. Heart J. 2010, 31:1088-1097.
12. Branton M.H., Schiffmann R., Sabnis S.G., Murray G.J., Quirk J.M., Altarescu G., Goldfarb L., Brady R.O., Balow J.E., Austin H.A., Kopp J.B. Natural history of Fabry renal disease: influence of alpha-galactosidase A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002, 81:122-138.
13. Hamers M.N., Westerveld A., Khan M., Tager J.M. Characterization of alpha-galactosidase isoenzymes in normal and Fabry human-Chinese Hamster somatic cell hybrids. Hum. Genet. 1977, 36:289-297.
14. Tajima Y., Kawashima I., Tsukimura T., Sugawara K., Kuroda M., Suzuki T., Togawa T., Chiba Y., Jigami Y., Ohno K., Fukushige T., Kanekura T., Itoh K., Ohashi T., Sakuraba H. Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease. Am. J. Hum. Genet. 2009, 85:569-580.
15. Altarescu G., Moore D.F., Schiffmann R. Effect of genetic modifiers on cerebral lesions in Fabry disease. Neurology 2005, 64:2148-2150.
16. Rohard I., Schaefer E., Kampmann C., Beck M., Gal A. Association between polymorphisms of endothelial nitric oxide synthase gene (NOS3) and left posterior wall thickness (LPWT) of the heart in Fabry disease. J. Inherit. Metab. Dis. 2008, Oct 22 [Epub ahead of print]. 10.1007/s10545-008-0920-z.
17. Desnick R.J., Ioannou Y.A., Eng C.M. α-Galactosidase A deficiency: Fabry disease. The metabolic and molecular bases of inherited disease 1996, 2741-2784. McGraw-Hill, New York. 6th ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
18. Sweeley C.C., Klionsky B. Fabry's disease: classification as a sphingolipidosis and partial characterization of a novel glycolipid. J. Biol. Chem. 1963, 238:3148-3150.
19. Rombach S.M., Twickler T.B., Aerts J.M., Linthorst G.E., Wijburg F.A., Hollak C.E. Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol. Genet. Metab. 2010, 99:99-108.
20. Mills K., Vellodi A., Morris P., Cooper D., Morris M., Young E., Winchester B. Monitoring the clinical and biochemical response to enzyme replacement therapy in three children with Fabry disease. Eur. J. Pediatr. 2004, 163:595-603.
21. Fauler G., Rechberger G.N., Devrnja D., Erwa W., Plecko B., Kotanko P., Breunig F., Paschke E. Rapid determination of urinary globotriaosylceramide isoform profiles by electrospray ionization mass spectrometry using stearoyl-d35-globotriaosylceramide as internal standard. Rapid Commun. Mass Spectrom. 2005, 19:1499-1506.
22. Fuller M., Sharp P.C., Rozaklis T., Whitfield P.D., Blacklock D., Hopwood J.J., Meikle P.J. Urinary lipid profiling for the identification of Fabry hemizygotes and heterozygotes. Clin. Chem. 2005, 51:688-694.
23. Auray-Blais C., Cyr D., Mills K., Giguère R., Drouin R. Development of a filter paper method potentially applicable to mass and high-risk urinary screenings for Fabry disease. J. Inherit. Metab. Dis. 2007, 30:106.
24. Groener J.E., Poorthuis B.J., Kuiper S., Helmond M.T., Hollak C.E., Aerts J.M. HPLC for simultaneous quantification of total ceramide, glucosylceramide, and ceramide trihexoside concentrations in plasma. Clin. Chem. 2007, 53:742-747.
25. Whitfield P.D., Calvin J., Hogg S., O'Driscoll E., Halsall D., Burling K., Maguire G., Wright N., Cox T.M., Meikle P.J., Deegan P.B. Monitoring enzyme replacement therapy in Fabry disease-role of urine globotriaosylceramide. J. Inherit. Metab. Dis. 2005, 28:21-33.
26. Young E., Mills K., Morris P., Vellodi A., Lee P., Waldek S., Winchester B. Is globotriaosylceramide a useful biomarker in Fabry disease?. Acta Paediatr. 2005, 447(Suppl 94):51-54.
27. Bekri S., Lidove O., Jaussaud R., Knebelmann B., Barbey F. The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature. Cardiovasc. Hematol. Agents Med. Chem. 2006, 4:289-297.
28. Aerts J.M., Groener J.E., Kuiper S., Donker-Koopman W.E., Strijland A., Ottenhoff R., van Roomen C., Mirzaian M., Wijburg F.A., Linthorst G.E., Vedder A.C., Rombach S.M., Cox-Brinkman J., Somerharju P., Boot R.G., Hollak C.E., Brady R.O., Poorthuis B.J. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc. Natl Acad. Sci. U. S. A. 2008, 105:2812-2817.
29. Eng C.M., Guffon N., Wilcox W.R., Germain D.P., Lee P., Waldek S., Caplan L., Linthorst G.E., Desnick R.J. Safety and efficacy of recombinant human alpha-galactosidase A-replacement therapy in Fabry's disease. N Engl J. Med. 2001, 345:9-16.
30. Schiffmann R., Kopp J.B., Austin H.A., Sabnis S., Moore D.F., Weibel T., Balow J.E., Brady R.O. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001, 285:2743-2749.
31. Blom D., Speijer D., Linthorst G.E., Donker-Koopman W.G., Strijland A., Aerts J.M. Recombinant enzyme therapy for Fabry disease: absence of editing of human alpha galactosidase A mRNA. Am. J. Hum. Genet. 2003, 72:23-31.
32. de Fost M., Hollak C.E., Groener J.E., Aerts J.M., Maas M., Poll L.W., Wiersma M.G., Häussinger D., Brett S., Bril N., vom Dahl S. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: a 2-center retrospective analysis. Blood 2006, 108:830-835.
33. Vedder A.C., Linthorst G.E., Houge G., Groener J.E., Ormel E.E., Bouma B.J., Aerts J.M., Hirth A., Hollak C.E. Treatment of Fabry disease: outcome of a comparative trial with agalsidase alfa or beta at a dose of 0.2mg/kg. PLoS ONE 2007, 2:e598.
34. Mehta A., Beck M., Elliott P., Giugliani R., Linhart A., Sunder-Plassmann G., Schiffmann R., Barbey F., Ries M., Clarke J.T., Fabry Outcome Survey investigators Enzyme replacement therapy with agalsidase alfa in patients with Fabry's disease: an analysis of registry data. Lancet 2009, 374:1986-1996.
35. Knebelmann B., Kurschat C., Thadhani R. Enzyme therapy for Fabry's disease: registered for success?. Lancet 2009, 374:1950-1951.
36. Linthorst G.E., Hollak C.E., Donker-Koopman W.E., Strijland A., Aerts J.M. Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int. 2004, 66:1589-1595.
37. Ohashi T., Sakuma M., Kitagawa T., Suzuki K., Ishige N., Eto Y. Influence of antibody formation on reduction of globotriaosylceramide (GL-3) in urine from Fabry patients during agalsidase beta therapy. Mol. Genet. Metab. 2007, 92:271-273.
38. Vedder A.C., Breunig F., Donker-Koopman W.E., Mills K., Young E., Winchester B., Ten Berge I.J., Groener J.E., Aerts J.M., Wanner C., Hollak C.E. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol. Genet. Metab. 2008, 94:319-325.
39. Bénichou B., Goyal S., Sung C., Norfleet A.M., O'Brien F. A retrospective analysis of the potential impact of IgG antibodies to agalsidase beta on efficacy during enzyme replacement therapy for Fabry disease. Mol. Genet. Metab. 2009, 96:4-12.
40. Hollak C.E., Linthorst G.E. Immune response to enzyme replacement therapy in Fabry disease: impact on clinical outcome?. Mol. Genet. Metab. 2009, 96:1-3.
41. Rombach S.M., Dekker N., Bouwman M.G., Linthorst G.E., Zwinderman A.H., Wijburg F.A., Kuiper S., Vd Bergh Weerman M.A., Groener J.E., Poorthuis B.J., Hollak C.E., Aerts J.M. Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease. Biochim. Biophys. Acta 2010, May 13 [Epub ahead of print]. 10.1016/j.bbadis.2010.05.003.
42. Kobayashi T., Shinoda H., Goto I., Yamanaka T., Suzuki Y. Globoid cell leukodystrophy is a generalized galactosylsphingosine (psychosine) storage disease. Biochem. Biophys. Res. Commun. 1987, 144:41-46.
43. Giri S., Khan M., Nath N., Singh I., Singh A.K. The role of AMPK in psychosine mediated effects on oligodendrocytes and astrocytes: implication for Krabbe disease. J. Neurochem. 2008, 105:1820-1833.
44. White A.B., Givogri M.I., Lopez-Rosas A., Cao H., van Breemen R., Thinakaran G., Bongarzone E.R. Psychosine accumulates in membrane microdomains in the brain of Krabbe patients, disrupting the raft architecture. J. Neurosci. 2009, 29:6068-6077.
45. Sanchez-Niño M.D., Sanz A.B., Carrasco S., Saleem M.A., Mathieson P.W., Valdivielso J.M., Ruiz-Ortega M., Egido J., Ortiz A. Globotriaosylsphingosine actions on human glomerular podocytes: implications for Fabry nephropathy. Nephrol. Dial. Transplant. 2010, May 26 [Epub ahead of print]. 10.1093/ndt/gfq306.
46. Whybra C., Kampmann C., Krummenauer F., Ries M., Mengel E., Miebach E., et al. The Mainz Severity Score Index: a new instrument for quantifying the Anderson-Fabry disease phenotype, and the response of patients to enzyme replacement therapy. Clin. Genet. 2004, 65(4):299-307.